These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 3767191)

  • 1. New inotropic-vasodilating drugs in acute and chronic heart failure.
    Goenen MJ
    Ann Med Interne (Paris); 1986; 137(3):229-34. PubMed ID: 3767191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New positive inotropic drugs in acute and chronic heart failure].
    Follath F
    Schweiz Rundsch Med Prax; 1992 May; 81(21):704-7. PubMed ID: 1351309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Amrinone in acute and long-term therapy].
    Klepzig M; Kleinhans E; Büll U; Strauer BE
    Z Kardiol; 1985 Feb; 74(2):85-90. PubMed ID: 3922139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inodilator therapy for heart failure. Early, late, or not at all?
    Remme WJ
    Circulation; 1993 May; 87(5 Suppl):IV97-107. PubMed ID: 8097971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of amrinone administered orally and by injection in heart failure].
    Bounhoure JP; Massabuau P; Puel J; Miquel JP; Calazel J
    Ann Med Interne (Paris); 1985; 136(3):251-5. PubMed ID: 3896092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of inodilators.
    Dei Cas L; Metra M; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S60-71. PubMed ID: 2483442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac drugs: new inotropes.
    Kelleher RM
    Crit Care Nurs Clin North Am; 1989 Jun; 1(2):391-7. PubMed ID: 2818883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New oral drugs for the treatment of congestive heart failure].
    Hayashida W; Kumada T; Kawai C
    Nihon Rinsho; 1992 Feb; 50(2):413-9. PubMed ID: 1319514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacotherapy of severe heart failure with inodilators--new approaches].
    Baumann G; Hader O
    Z Kardiol; 1996; 85 Suppl 4():9-19. PubMed ID: 9027110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of amrinone in acute severe cardiac failure.
    Heuer H; Frenking B; Gülker H
    Arzneimittelforschung; 1988 Apr; 38(4):567-70. PubMed ID: 3401270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
    De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
    Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of inotropic agents.
    Vroom MB
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):246-52. PubMed ID: 16959760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful?
    Chatterjee K; Wolfe CL; DeMarco T
    Cardiol Clin; 1994 Feb; 12(1):63-72. PubMed ID: 8181026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.